Essential Skills for 21st Century Survival (Part 6)
This is part 6 in a 12 part series. The first five skills were Pattern Recognition, Environmental Scanning, Network Weaving, Foresight, and Conscious Awareness Storytelling The following video by Jonah Sachs, creative director at Free Range Studios has prompted me to get back to completing the next installment in this Essential Skills series.
5 Ways Small Businesses can Innovate Like the Big Guys
In traditional thinking, being competitive in the global marketplace requires a significant investment in time and resources. But the reality is that any organization today can take advantage of open innovation to innovate faster and cheaper than ever before, positioning them as true competition in the industry. This article will explore the top five ways SMEs can leverage open innovation.
Seoul Design Foundation
Origin of communication of Design·Creation Inustry, DDP DDP is the biggest three dimensional atypical building in the world as the world's first ‘Origin of Communication of Design·Creation Industry ’ and ‘Forward Base of Creation Industry’ to drive the future growth of Seoul. It was designed by Zaha Hadid, the world's architect and consists of five facilities for announcement of new product and exhibition, public performance, business, shopping and relaxation. DDP presents all the people with more rich life and creative inspiration by useful contents and efficient management.
The ultimate guide for the ambitious Innovation Manager (100+ sources)
Running innovation projects is hard. By definition you’re doing new things so you can’t rely on old habits and routines. If you and your innovation team don’t feel uncomfortable, you’re simply not innovating. That doesn’t mean you’ll need to fly blind. At every moment in your innovation process you can use tools, references, checklists and other innovation methods. We do the same in our innovation projects.
Blogs
可持续性设计 By Jonas Damon - March 31, 2014 其实设计并不像大众看起来那么简洁明了。往往产品最终看起来井然有序，但在达到那个结果的过程中是凌乱无章的，并且伴随着一些被遗弃在地板上的犹如碎片般堆积的创意、愿景和可能性。
New Efficient Reagent for Stem Cell Transfection
DreamFect™ Stem transfection reagent from Oz Biosciences is specifically developed for transfection of Stem Cell. Marseille, France, February 23, 2013 --(PR.com)-- OZ Biosciences SAS, specialized in the development of innovative transfection technologies is delighted to announce the launching of this new product DreamFect™ Stem. Stem cells are widely investigated due to their regenerative potential. In many cases, it would prove useful to enhance or silence some of their features through gene delivery strategies to harness their full potential cell/gene-based therapy. Because stem cells behavior, physiology and properties are quite distinctive to other cells, OZ Biosciences has developed a specific transfection reagent for stem cells.
Fierce's top 5 feats in life sciences 'gamification'
In less than 10 minutes, I aligned gene sequences from humans and several other species, spotted malaria-causing parasites in microscopy images, and took wild guesses about which types of cancer were linked with specific genes. It was all done without advanced training in genetics or pathology. Welcome to the "gamification" of life sciences research, where all you need is an Internet-connected device and a few minutes to play a part in advancing science. It's a growing trend within the open innovation and crowdsourcing movements sweeping the biopharma world. From mind-numbingly simple to technically challenging, the games offer a way to tap the masses in order to solve large and small problems. What an idea: Use addictive gaming environments to conquer Big Data challenges in genomics, test computer-driven methods of diagnosing infectious disease and determine cancer prognoses.
Stem cell treatment could accelerate diabetic wound healing
There's no question that diabetes is on the rise worldwide. In the U.S., about 26 million children are diabetic, and roughly 347 million people across the globe have the disease. The World Health Organization estimates that diabetes will be the seventh leading cause of death in 2030. Up to 25% of this population will get a foot ulcer at some point in their life.
Incisionless antiobesity device gets CE Mark
An incisionless, implantable antiobesity medical device from EndoSphere has received the CE Mark, which signifies European regulatory approval. EndoSphere’s device, called the Satisphere, works by slowing the passage of food through the duodenum, the upper part of the smaller intestine that breaks down food. Because food is in contact with the duodenum for a longer time, the device essentially fools the body into thinking that it’s consumed more food than it actually has. The company says the device helps patients lose weight without requiring surgery or medication. The device, which is inserted using an endoscope, can be placed in the small intestine in about 15 minutes, taken out in five minutes, if necessary, and doesn’t require any suturing or hooks to hold it in place.
Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study
Exenatide is a licensed, safe and effective treatment for patients with Diabetes mellitus. Laboratory work has shown strong, reproducible evidence that this drug has beneficial "disease modifying" effects when given to animals with a range of experimental models of Parkinson's disease (PD). This project aims to make an initial evaluation of possible benefits of Exenatide among patients with moderate symptoms of PD. The drug will be given as a twice daily 10microgram injection under the skin in a similar way to one of the conventional "symptomatic" treatments for PD (Apomorphine).
20 Major Pharma-Academic Alliances in 2012
By Skye Toor and Ryan McBride Big Pharma companies' insatiable needs for growing their pipelines and grabbing dibs on hot new science send them running to academic labs. With some pharma groups slashing internal R&D, drugmakers have taken a shining to funding discovery and early R&D work at universities and academic medical centers. Pharma groups have dabbled in commercializing innovations from academia for decades, but what's happened more recently is a drive to expand the number and breadth of collaborations with academics and other external groups. Traditional pharma players such as Sanofi ($SNY), Eli Lilly ($LLY) and Pfizer ($PFE) have realized that their internal R&D groups alone aren't enough. Here we've rounded up 20 notable pharma-academic collaborations from 2012 or those that made headlines this year.
